SHR-1603
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Physiological Effects of Drugs
Conditions
Physiological Effects of Drugs, Neoplasms by Histologic Type, Lymphoma, Hematologic Neoplasms, Immunotherapy, Advanced Cancer
Trial Timeline
Nov 13, 2018 → Oct 1, 2021
NCT ID
NCT03722186About SHR-1603
SHR-1603 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Physiological Effects of Drugs. The current trial status is active. This product is registered under clinical trial identifier NCT03722186. Target conditions include Physiological Effects of Drugs, Neoplasms by Histologic Type, Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03722186 | Phase 1 | Active |
Competing Products
1 competing product in Physiological Effects of Drugs
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CP-866,087 + CP-866,087 + CP-866,087 + Placebo | Pfizer | Phase 2 | 51 |